Chimeric IgG1 anti-EGFR monoclonal antibody that blocks EGFR signaling and can induce NK cell–mediated ADCC.
Chimeric IgG1 anti-EGFR monoclonal antibody that binds the extracellular domain of EGFR, blocking ligand binding and receptor dimerization to inhibit downstream signaling (RAS/RAF/MEK/ERK and PI3K/AKT), suppress tumor cell proliferation, and engage Fc-mediated NK cell–dependent ADCC.
YES
DIRECT
Cetuximab binds EGFR on target cells and engages Fcγ receptors (e.g., CD16) on NK cells to mediate ADCC, with possible complement-dependent cytotoxicity, killing EGFR+ cells.
Chimeric IgG1 anti-EGFR monoclonal antibody that blocks EGFR signaling and can induce NK cell–mediated ADCC.
Chimeric IgG1 anti-EGFR monoclonal antibody that binds the extracellular domain of EGFR, blocking ligand binding and receptor dimerization to inhibit downstream signaling (RAS/RAF/MEK/ERK and PI3K/AKT), suppress tumor cell proliferation, and engage Fc-mediated NK cell–dependent ADCC.
NO
INDIRECT
Cetuximab binds EGFR on tumor cells and engages CD16a on NK cells via its Fc to trigger ADCC that kills EGFR+ targets; CD16a-expressing cells act as effectors and are not directly killed.
Intravenous bispecific T‑cell–engaging monoclonal antibody that binds FcRH5 on malignant plasma cells and CD3 on T cells to redirect T‑cell cytotoxicity.
Bispecific antibody that binds FcRH5 on malignant plasma cells and CD3 on T cells, crosslinking and activating cytotoxic T cells to mediate targeted lysis of FCRH5-expressing myeloma cells.
YES
DIRECT
Cevostamab bridges CD3 on T cells to FCRH5 on target cells, activating T cells to kill FCRH5-expressing cells via perforin/granzyme-mediated cytotoxicity.
Intravenous bispecific T‑cell–engaging monoclonal antibody that binds FcRH5 on malignant plasma cells and CD3 on T cells to redirect T‑cell cytotoxicity.
Bispecific antibody that binds FcRH5 on malignant plasma cells and CD3 on T cells, crosslinking and activating cytotoxic T cells to mediate targeted lysis of FCRH5-expressing myeloma cells.
NO
INDIRECT
Cevostamab binds CD3 on T cells to activate and redirect them to kill FCRH5-positive myeloma cells via T-cell cytotoxicity (perforin/granzyme); CD3+ T cells are not the cells being killed.
Biosimilar chimeric IgG1 anti–TNF-α monoclonal antibody. Binds soluble and transmembrane TNF-α, blocks TNFR1/TNFR2 signaling, induces apoptosis and immune clearance of TNF-expressing cells via ADCC/CDC, and suppresses NF-κB–mediated inflammation and associated cytokines.
Chimeric IgG1 anti-TNF-alpha monoclonal antibody (biosimilar infliximab) that binds soluble and transmembrane TNF-alpha, neutralizing it and blocking TNFR1/TNFR2 signaling; also mediates ADCC and CDC to deplete TNF-expressing cells, leading to suppression of NF-kB-driven inflammation and proinflammatory cytokines.
NO
INDIRECT
The antibody neutralizes soluble TNF-α and blocks TNFR signaling; binding the soluble ligand does not directly kill cells.